<DOC>
	<DOCNO>NCT00349245</DOCNO>
	<brief_summary>The objective study determine efficacy safety Dexmedetomidine , selective alpha-2 adrenoceptor agonist , recently gain increased popularity ICU intraoperative sedation sedative awake fiberoptic intubation , compare Remifentanil . The hypothesis Dexmedetomidine provide least equal good condition ( sedation analgesia ) require awake fiberoptic intubation ( Ramsay Sedation Scale 3 ) less respiratory cardiovascular adverse effect , well less recall Remifentanil .</brief_summary>
	<brief_title>Dexmedetomidine vs. Remifentanil Sedation During AFI</brief_title>
	<detailed_description>Awake nasal oral fiberoptic intubation remain method choice airway management expect difficult airway . This technique require patient comfortable , relaxed , cooperative able maintain airway spontaneous ventilation . In order achieve condition , pharmacologic agent choose sedation short act highly titratable , provide required amount sedation little suppression spontaneous ventilation . There numerous report use Remifentanil Propofol use either alone combination achieve level sedation . Remifentanil follow advantage make useful drug purpose : 1 . Ultra short act constant half life 2 . Anti-tussive effect help prevent cough tracheal manipulation 3 . Reversible antagonist naloxone 4 . Attenuates cardiovascular response laryngoscopy Shortcomings Remifentanil include undesirable side effect , hemodynamic instability respiratory depression . Dexmedetomidine centrally act , selective alpha-2 agonist gain increase popularity since 1999 drug sedation ICU setting . It also use intraoperative sedation surgery regional anesthesia awake craniotomy , well sedation pediatric patient different setting . Finally , also case report Dexmedetomidine use awake fiberoptic tracheal intubation . Theoretically , pharmacokinetic pharmacodynamic property Dexmedetomidine make ideal drug single agent sedation awake fiberoptic intubation . Venn et al show healthy individual ICU patient , Dexmedetomidine show rapid onset equally rapid distribution half life quick recovery . This study also demonstrate stable hemodynamics airway manipulation ( extubation ) adverse cardiovascular respiratory event study . Other study demonstrate Dexmedetomidine attenuate cardiovascular response laryngoscopy intubation reduces need perioperative opioids . In small dos , demonstrate good sedative , amnestic analgesic effect , well anti-sialogogue effect . Dexmedetomidine , however , drawback . In high bolus dos cause hemodynamic change , excessive bradycardia hypertension follow hypotension . This drug also associate decreased regional global cerebral blood flow despite maintenance MAP within auto-regulating parameter . These deleterious effect prominent patient hypovolemia , systemic vasoconstriction , AV block rapid bolus infusion .</detailed_description>
	<mesh_term>Dexmedetomidine</mesh_term>
	<mesh_term>Remifentanil</mesh_term>
	<criteria>A sign informed consent must obtain nature study fully explain . Patients undergoing procedure require general anesthesia endotracheal tube . Patients assess attend anesthesiologist airway require awake fiberoptic intubation . Adult patient &gt; 18 yr . old , ASA I III . Patients expect severe adverse side effect Dexmedetomidine include : 1 . Previous allergy drug . 2 . 3rd degree AV Block 3 . Hypovolemic hypotension 4 . Systemic vasoconstriction Patients expect severe adverse side effect Remifentanil . This include : 1 . Previous allergy drug . 2 . Patients suspect overly sensitive narcotic . Patients significant cardiovascular disease ASA physical status IV V</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Endotracheal</keyword>
	<keyword>Awake fiberoptic intubation</keyword>
	<keyword>Dexmedetomidine</keyword>
	<keyword>Remifentanil</keyword>
</DOC>